Recently the treatment of intractable schizophrenia is the current concern of researchers. The purposes of this study were to investigate the efficacy of alprazolam as a neuroleptic adjunct for chronic schizophrenia. The subjects consisted of 46 inpatients who were diagnosed as schizophrenia based on DSM-III-R criteria. The subjects were randomly assigned to receive either alprazolam and neuroleptics, or placebo and neuroleptics. The maximum dosage of alprazolam was 4.5mg per day, and the duration of study was 6 weeks. Clinical evaluation with HAR S (Hamilton’s Anxiety Rating Scale) and BPRS (Brief Psychiatric Rating Scale) were done weekly on the double-blind method. The results of study showed that alprazolam produced significantly more clinical improvement than placebo in anxiety that included somatic concern, anergia subscale, and hostile-suspiciousness subscale. But BPRS total score, thought disturbance subscale, and activatation subscale showed no significant correlation between alprazolam-treated inpatient group and placebo-treated inpatient group. The side effects of alprazolam were not reported, except that the only one patient who received alprazolam, had side effect of daytime drowsiness
서 론
연구대상 및 방법
연 구 결 과
고 찰
결 론
참 고 문 헌